Agilent Technologies Denmark ApS recalled 65 units of its FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26 on August 11, 2025. The recall stems from potential weak staining that could lead to false negative CD20 identification. Healthcare providers and patients should stop using the product immediately.
Their is the potential for weak staining which may result in false negative CD20 identification.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Agilent Technologies Denmark ApS or your healthcare provider for instructions. Notification method: N/A
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, with catalog number GA60461-2CN. It was distributed nationwide in the U.S. The lot numbers affected include 41781549, 41762487, and 41651581.
The product may show weak staining, potentially resulting in false negative identification of CD20. This could impact the classification of B-cell neoplasms.
As of the report date, no specific incidents or injuries have been documented related to the recall. The potential for inaccuracies in test results poses a significant risk.
Stop using the product immediately. Follow the recall instructions provided by Agilent Technologies. Contact your healthcare provider for further guidance.
For more information, reach Agilent Technologies Denmark ApS. Visit their website or call their support line for assistance.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.